异基因造血干细胞移植前后监测NUP98::NSD1融合基因的临床意义
该研究纳入16例NUP98::NSD1融合基因阳性急性髓系白血病患者,观察异基因造血干细胞移植前后融合基因表达动态变化并分析其作为可检测残留病指标的价值。中位随访526天,4例(25.0%)血液学复发,移植后NUP98::NSD1阳性患者复发率更高,且该指标较流式细胞术残留和WT1更敏感。
要点
- 移植后NUP98::NSD1阳性患者44.4%复发,阴性患者无复发。
- 移植后NUP98::NSD1水平预测复发的ROC曲线下面积为1.000(95%CI 1.000~1.000,P=0.003)。
- 4例复发患者中NUP98::NSD1较流式细胞术残留和WT1更敏感。
核心结论
- NUP98::NSD1融合基因可用于评估该类急性髓系白血病的可检测残留病状态。
- 移植后NUP98::NSD1阳性患者复发率高、预后差。
- NUP98::NSD1比流式细胞术残留和WT1预测移植后复发更为敏感。
研究设计与样本
- 本研究为观察性研究,纳入16例在北京大学人民医院诊断为NUP98::NSD1融合基因阳性并接受异基因造血干细胞移植的急性髓系白血病患者。
- 移植前后监测NUP98::NSD1融合基因和白血病相关免疫表型以评估可检测残留病状态。
主要发现
- 所有患者中位随访时间为526天(139~1136天),4例(25.0%)在移植后中位474天(283~607天)出现血液学复发。
- 3例(18.8%)患者死亡,其中2例(12.5%)死于白血病复发。
- 数据齐全的初诊患者初诊时NUP98::NSD1中位表达水平为78.550%(18.900%~184.400%)。
- 移植后NUP98::NSD1阳性患者中44.4%发生复发,移植后NUP98::NSD1阴性患者中无复发。
- 移植后NUP98::NSD1水平预测复发的ROC曲线下面积为1.000(95%CI 1.000~1.000,P=0.003)。
临床怎么用
- 作者认为NUP98::NSD1融合基因可用于评估该类急性髓系白血病异基因造血干细胞移植后的可检测残留病状态。
- 作者认为移植后NUP98::NSD1阳性患者复发率高、预后差,该指标较流式细胞术残留和WT1预测移植后复发更为敏感。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: This study aimed to observe the dynamic changes of NUP98::NSD1 expression before and after allogeneic hematopoietic stem cell transplantation (allo-HSCT) . Moreover, the clinical value of measurable residual disease (MRD) was analyzed. Methods: Sixteen AML patients who were diagnosed with the NUP98::NSD1 fusion gene and received allo-HSCT at Peking University People's Hospital were included. The NUP98::NSD1 fusion gene and leukemia-associated immunophenotype (LAIP) were monitored before and after transplantation to evaluate their MRD status. Results: The median follow-up time for all patients was 526 days (139-1136 days) , with four patients (25.0%) experiencing hematological recurrence at a median of 474 days (283-607 days) after transplantation. Three patients (18.8%) died, two of whom (12.5%) died of leukemia recurrence. The median expression level of NUP98::NSD1 in newly diagnosed patients with complete data was 78.5% (18.9%-184.4%) at the time of initial diagnosis. The recurrence rate was higher in NUP98::NSD1-positive patients after transplantation, with 44.4% of patients experiencing recurrence, whereas no recurrence occurred in NUP98::NSD1-negative patients after transplantation. The area under the receiver operating characteristic curve predicted by the NUP98::NSD1 level after transplantation was 1.000 (95% confidence interval: 1.000-1.000, P=0.003) . Among the four patients with recurrence, NUP98::NSD1 was more sensitive than flow cytometry residual (FCM) and Wilms' tumor gene 1 (WT1) . Conclusions: The NUP98::NSD1 fusion gene can be used to evaluate the MRD status of allo-HSCT. NUP98::NSD1-positive patients after transplantation have a high relapse rate and poor prognosis. NUP98::NSD1 was more sensitive than FCM and WT1 in predicting posttransplant relapse. 目的: 观察急性髓系白血病(AML)患者异基因造血干细胞移植(allo-HSCT)前后核孔蛋白98(NUP98)::NSD1融合基因表达的动态变化,并初步分析其作为可检测残留病(MRD)评估指标预测移植后白血病复发的临床价值。 方法: 16例在北京大学人民医院诊断为NUP98::NSD1融合基因阳性AML并接受allo-HSCT的患者纳入研究,移植前后监测NUP98::NSD1融合基因、流式细胞术(FCM)检测白血病免疫残留等指标来评估其MRD状态。 结果: 所有患者中位随访时间为526(139~1136)d,共有4例(25.0%)患者在移植后出现血液学复发,中位复发时间为474(283~607)d。3例(18.8%)患者死亡,其中2例(12.5%)死于白血病复发。数据齐全的初诊患者在初诊时NUP98::NSD1的中位表达水平为78.550%(18.900%~184.400%)。移植后NUP98::NSD1阳性患者复发率更高,NUP98::NSD1阳性患者中44.4%发生复发,移植后NUP98::NSD1阴性患者中无发生复发。移植后NUP98::NSD1水平预测复发的ROC曲线下面积(AUC)=1.000(95%CI 1.000~1.000,P=0.003)。4例复发患者中,NUP98::NSD1较FCM检测免疫残留和Wilms肿瘤基因1(WT1)更为敏感。 结论: NUP98::NSD1融合基因可用于评估该类AML的MRD状态。移植后NUP98::NSD1阳性患者复发率高,预后差。NUP98::NSD1比FCM和WT1预测移植后复发更为敏感。.
引用
- Shang YK, Pan XA, Chang YJ, et al. [Clinical significance of monitoring NUP98::NSD1 fusion genes before and after allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 38503524. doi:10.3760/cma.j.issn.0253-2727.2023.12.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。